Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 5/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 9/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 8/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 7/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431662 | 0.85 | TNF (0.71) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL2067332 | 0.81 | TNF (0.50) | TNFKDM4E | |
| SCHEMBL432525 | 0.81 | TNF (0.61) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL2065119 | 0.78 | TNF (0.47) | TNF | |
| SCHEMBL2066384 | 0.78 | TNF (0.47) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL2068600 | 0.78 | TNF (0.47) | TNF | |
| SCHEMBL1202637 | 0.76 | TNF (0.59) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL2066212 | 0.75 | TNF (0.44) | TNF | |
| SCHEMBL1203666 | 0.75 | TNF (0.70) | TNFALDH1A1SMN1; SMN2 | |
| SCHEMBL2066089 | 0.74 | TNF (0.43) | TNFALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012259-B1 | FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-9988381-B2 | Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20160137640-A1 | FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO. LTD. (CN) | 2016-05-19 | — | — | US | disclosed |
| EP-3012259-A1 | FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137640-A1 | FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF | ABL1, JAK2, LCK | TNF 1549/4885DYRK1A 135/4885DYRK2 63/4885 |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | TNF 4372/4885DYRK1A 588/4885DYRK2 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.